Silvercrest Asset Management Group LLC Uni Qure N.V. Transaction History

Silvercrest Asset Management Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $103,941 - $152,680	-18,462 Reduced 7.28%	235,205 $1.59 Million
Q3 2023 Nov 14, 2023	SELL	$6.71 - $11.83 $4,307 - $7,594	-642 Reduced 0.25%	253,667 $1.7 Million
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $1.35 Million - $2.7 Million	121,654 Added 91.71%	254,309 $2.91 Million
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $602,588 - $743,407	32,224 Added 32.09%	132,655 $2.67 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $1.82 Million - $2.74 Million	100,431 New	100,431 $2.28 Million

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $266M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.